Literature DB >> 33357746

Geographic Variation in Anticoagulant Use and Resident, Nursing Home, and County Characteristics Associated With Treatment Among US Nursing Home Residents.

Matthew Alcusky1, Jonggyu Baek2, Jennifer Tjia2, David D McManus3, Kate L Lapane2.   

Abstract

OBJECTIVES: To quantify geographic variation in anticoagulant use and explore what resident, nursing home, and county characteristics were associated with anticoagulant use in a clinically complex population.
DESIGN: A repeated cross-sectional design was used to estimate current oral anticoagulant use on December 31, 2014, 2015, and 2016. SETTING AND PARTICIPANTS: Secondary data for United States nursing home residents during the period 2014-2016 were drawn from the Minimum Data Set 3.0 and Medicare Parts A and D. Nursing home residents (≥65 years) with a diagnosis of atrial fibrillation and ≥6 months of Medicare fee-for-service enrollment were eligible for inclusion. Residents in a coma or on hospice were excluded.
METHODS: Multilevel logistic models evaluated the extent to which variation in anticoagulant use between counties could be explained by resident, nursing home, and county characteristics and state of residence. Proportional changes in cluster variation (PCVs), intraclass correlation coefficients (ICCs), and adjusted odds ratios (aORs) were estimated.
RESULTS: Among 86,736 nursing home residents from 11,860 nursing homes and 1694 counties, 45% used oral anticoagulants. The odds of oral anticoagulant use were 18% higher in 2016 than 2014 (aOR: 1.18; 95% confidence interval: 1.14-1.22). Most states had counties in the highest (51.3-58.9%) and lowest (31.1%-41.4%) deciles of anticoagulant use. Compared with the null model, adjustment for resident characteristics explained one-third of the variation between counties (PCV: 34.8%). The full model explained 65.5% of between-county variation. Within-county correlation was a small proportion (ICC < 2.2%) of total variation. CONCLUSIONS AND IMPLICATIONS: In this older adult population at high risk for ischemic stroke, less than half of the residents received treatment with anticoagulants. Variation in treatment across counties was partially attributable to the characteristics of residents, nursing homes, and counties. Comparative evidence and refinement of predictive algorithms specific to the nursing home setting may be warranted.
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; anticoagulants; nursing homes

Mesh:

Substances:

Year:  2021        PMID: 33357746      PMCID: PMC8092949          DOI: 10.1016/j.jamda.2020.10.001

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  47 in total

1.  Does Nursing Home Compare Reflect Patient Safety In Nursing Homes?

Authors:  Daniel Brauner; Rachel M Werner; Tetyana P Shippee; John Cursio; Hari Sharma; R Tamara Konetzka
Journal:  Health Aff (Millwood)       Date:  2018-11       Impact factor: 6.301

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

3.  Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States.

Authors:  Richard H White; Martina Garcia; Banafsheh Sadeghi; Daniel J Tancredi; Patricia Zrelak; Joanne Cuny; Pradeep Sama; Harriet Gammon; Stephen Schmaltz; Patrick S Romano
Journal:  Thromb Res       Date:  2010-04-28       Impact factor: 3.944

4.  Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents.

Authors:  Andrew R Zullo; Sadia Sharmin; Yoojin Lee; Lori A Daiello; Nishant R Shah; W John Boscardin; David D Dore; Sei J Lee; Michael A Steinman
Journal:  J Am Geriatr Soc       Date:  2017-10-17       Impact factor: 5.562

5.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors:  Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal:  Chest       Date:  2009-09-17       Impact factor: 9.410

6.  Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.

Authors:  Sripal Bangalore; Robert Fakheri; Bora Toklu; Gbenga Ogedegbe; Howard Weintraub; Franz H Messerli
Journal:  Mayo Clin Proc       Date:  2016-01       Impact factor: 7.616

7.  Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation.

Authors:  Wesley T O'Neal; Pratik B Sandesara; J'Neka S Claxton; Richard F MacLehose; Lin Y Chen; Lindsay G S Bengtson; Alanna M Chamberlain; Faye L Norby; Pamela L Lutsey; Alvaro Alonso
Journal:  J Am Heart Assoc       Date:  2018-03-10       Impact factor: 5.501

8.  Changes in Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 to 2016.

Authors:  Matthew Alcusky; David D McManus; Anne L Hume; Marc Fisher; Jennifer Tjia; Kate L Lapane
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

Review 9.  Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis.

Authors:  Vikram R Comondore; P J Devereaux; Qi Zhou; Samuel B Stone; Jason W Busse; Nikila C Ravindran; Karen E Burns; Ted Haines; Bernadette Stringer; Deborah J Cook; Stephen D Walter; Terrence Sullivan; Otavio Berwanger; Mohit Bhandari; Sarfaraz Banglawala; John N Lavis; Brad Petrisor; Holger Schünemann; Katie Walsh; Neera Bhatnagar; Gordon H Guyatt
Journal:  BMJ       Date:  2009-08-04

10.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors:  Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.